BoJ rate cut has become more likely late this year.

At its June 19-20 meeting, the Bank of Japan (BoJ) policy board held its monetary policy constant with a majority vote of seven to two, while the two most dovish board members Harada and Kataoka argued for more easing.

  • Market Commentary

Highlights:

  • At its June 19-20 meeting, the Bank of Japan (BoJ) policy board left its monetary policy unchanged. It also gave no obvious hint that it would follow the much more dovish Fed or ECB soon.
  • However, given that we now expect two key rate cuts by the Fed this year, the BoJ could also be forced into action. We now see it as slightly more likely than not that the BoJ cuts its short term policy rate by 20 bps.
  • This expected rate cut depends very much on the Fed policy to maintain its dovish tilt, but also on a persistent strength of the yen, a continued cyclical slowing of growth in Japan’s dominant trading partners which backfires on domestic capex as well as Japan’s inflation rate to ease again.
  • Given the BoJ’s already stretched policy tools, the BoJ action would be accompanied by further measures to mitigate its negative side effects. Currently, markets discuss a range of options, of which an extension of the loan program looks the most likely.
  • Regarding the timing of the cut, market views still switch between October and December. Although we see a second Fed cut likely in September, we consider a rate cut in December the more likely date for the time being.

Download the full publication below

BOJ RATE CUT HAS BECOME
MORE LIKELY LATE
THIS YEAR.
DOWNLOAD
PDF
MORE INSIGHTS

RELATED INSIGHTS

READ NOW
CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
READ NOW
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
READ NOW
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
MORE INSIGHTS